ROCHE TAPS RECURSION AI FOR BRAIN DISEASE RESEARCH

Recursion uses machine learning and high-throughput biology to analyze vast datasets and identify disease targets faster than traditional methods. The partnership focuses on uncovering novel therapeutic approaches for neurological conditions. Roche, one of the world's largest pharmaceutical companies, joins a growing number of drugmakers investing in AI-driven discovery. These platforms claim to reduce failure rates in clinical trials by better predicting which compounds will succeed. Recursion's approach combines computational analysis with wet-lab experimentation, creating feedback loops that refine predictions. The company has raised significant funding to scale its platform across multiple disease areas. The deal represents pharmaceutical industry confidence in AI's potential to address the high costs and timelines of drug development. Industry analysts estimate that failed trials cost billions annually, making efficiency gains valuable for both companies and patients awaiting new treatments.